Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug

Xenobiotica

Volumn 38, Issue 3, 2008, Pages 340-352

  Khojasteh, S C ^a   Leipold, D D ^a   Lai, F ^b   La, H ^a   Baumgardner, M J ^a   Desino, K E ^c   Gudmundsson, O S ^d   Bloedow, D C ^e   Bodary, S C ^f   Reynolds, M E ^a   Gadek, T R ^g   Kenkare Mitra, S ^a  

^a GENENTECH INC   (United States)

^b Varian Inc   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g SARcode Corporation   (United States)

Author keywords

Distribution; Esterase; Intercellular adhesion molecule (ICAM); Lymphocyte function associated antigen 1 (LFA 1); Metabolism and excretion (ADME); metabolism; Pharmacokinetics; Prodrug; absorption

Indexed keywords

ANTIINFLAMMATORY AGENT; CARBON 14; INTRACELLULAR ADHESION MOLECULE 1988; INTRACELLULAR ADHESION MOLECULE 2660; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE; LIVER; MALE; MONKEY; MOUSE; NONHUMAN; PLASMA; RAT;

ABSORPTION; ACRYLAMIDES; ANIMALS; BETA-ALANINE; CELL ADHESION MOLECULES; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HAPLORHINI; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICE; PRODRUGS; RATS; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; MUS; RATTUS;

EID: 39349084275     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701813248     Document Type: Article

References (13)

1. Anderson ME, Siahaan TJ. 2003. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: Designing peptide and small molecule inhibitors. Peptides 24:487-501.
2. Beaumont K, Webster R, Gardner I, Dack K. 2003. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Current Drug Metabolism 4:461-485.
3. Burdick DJ, Marsters Jr JC, Aliagas-Martin I, Stanley M, Beresini M, Clark K, McDowell RS, Gadek TR. 2004. N-benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: Structure-activity relationship of the benzoyl moiety. Bioorganic and Medicinal Chemistry Letters 14(9):2055-2059.
4. Burdick DJ, Paris K, Weese K, Stanley M, Beresini M, Clark K, McDowell RS, Marsters JC, Gadek TR. 2003. N-benzoyl amino acids as LFA-1/ICAM inhibitors 1: Amino acid structure-activity relationship. Bioorganic and Medicinal Chemistry Letters 13:1015-1018.
5. Emeigh J, Gao DA, Goldberg DR, Kuzmich D, Miao C, Potocki I, Qian KC, Sorcek RJ, Jeanfavre DD, et al. 2004. Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-a]imidazol-2-one derivatives. Journal of Medicinal Chemistry 47:5356-5366.
6. Gachon F, Nicolas C, Maurizis JC, Verny M, Chabard JL, Faurie M, Gaillard G. 1988. Disposition and metabolism of letosteine in rats. Drug Metabolism and Disposition 16:853-857.
7. Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC, Paris KJ, Oare DA, Reynolds ME, Ladner C, Zioncheck KA, et al. 2002. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295:1086-1089.
8. Gudmundsson OS, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, Borchardt RT. 1999. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharmaceutical Research 16:7-15.
9. Keating S, Clark K, Stefanich L, Arellano F, Edwards C, Bodary, Spencer S, Gadek T, Marsters Jr J, Beresini M. 2006, Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alpha subunit of lymphocyte function associated antigen-1. Protein Science 15:290-303.
10. Liu L, Link JT, Pei Z, Reilly EB, Leitza S, Nguyen B, Marsh KC, Okasinski GF, Von Geldern TW, Ormes M, et al. 2000. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/ intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. Journal of Medicinal Chemistry 43:4025-4040.
11. National Institutes of Health National Research Council. 1996. Guide for the Care and Use of Laboratory Animals.
12. Roberts J. 1992. Amino acids and their derivatives as radioprotective agents. Amino Acids 3:25-52.
13. Yonekawa K, Harlan JM. 2005. Targeting leukocyte integrins in human diseases. Journal of Leukocyte Biology 77:129-140.